GI-Targeted Indane NHE Inhibitors for Fluid Retention Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for disorders associated with fluid retention and salt overload, such as congestive heart failure, chronic kidney disease, and gastrointestinal tract disorders, are inadequate, often causing side effects like renal impairment, fluid resistance, and systemic complications, and lack effective, non-systemic NHE inhibitors targeting the gastrointestinal tract.
Innovation Solution
Development of indane derivatives that inhibit NHE-mediated antiport of sodium and hydrogen ions, primarily acting in the gastrointestinal tract, to reduce fluid and salt retention and alleviate gastrointestinal disorders without systemic side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If diuretics are used to treat fluid retention and salt overload, then fluid volume is reduced, but renal impairment and systemic side effects occur
Solution Approach 1:
The patent extracts the NHE inhibition function specifically to the gastrointestinal tract using non-absorbable compounds, separating this therapeutic action from systemic diuretic effects on the kidneys. This allows fluid management without renal impairment by targeting only the GI tract NHE isoforms (particularly NHE3) that handle luminal sodium and water absorption.
Solution Approach 2:
The invention applies local quality by using compounds that are non-absorbable and remain confined to the gastrointestinal lumen, creating a localized therapeutic effect at the site of NHE-mediated sodium and water absorption without systemic circulation. This ensures the drug acts only where needed (GI tract) and avoids systemic side effects including renal impairment.
2Quantity of substance
If loop diuretics are used to treat pulmonary edema, then fluid removal is enhanced, but diuretic resistance develops
Solution Approach 1:
The patent extracts the diuretic effect from the renal system to the gastrointestinal system by inhibiting NHE-mediated sodium and water absorption in the gut. This alternative pathway for fluid removal bypasses the renal mechanisms that develop resistance, providing a reliable complementary or alternative approach to fluid management.
Solution Approach 2:
Instead of promoting fluid excretion through the kidneys (traditional diuretic approach), the invention inverts the approach by preventing fluid absorption in the gastrointestinal tract. This reverse strategy achieves fluid removal by blocking absorption rather than promoting excretion, thereby avoiding diuretic resistance mechanisms.
3Quantity of substance
If thiazides are used to inhibit NaCl transport, then sodium reabsorption is prevented, but effectiveness is lost when GFR is less than 30 ml/min
Solution Approach 1:
The patent extracts sodium inhibition from the renal tubules (where thiazides act) to the gastrointestinal lumen (where NHE inhibitors act). This relocation allows sodium absorption inhibition to function independently of glomerular filtration rate, since the mechanism depends on luminal sodium concentration rather than filtered sodium load.
Solution Approach 2:
The invention changes the operational parameter from GFR-dependent renal sodium handling to GFR-independent gastrointestinal sodium absorption. By targeting NHE-mediated sodium-coupled water absorption in the gut, the therapy maintains effectiveness across all GFR levels, including severe renal impairment where traditional diuretics fail.
4Quantity of substance
If diuretics are used to reduce fluid volume, then cardiac output is reduced, but fatigue and dizziness replace CHF symptoms
Solution Approach 1:
The patent extracts the fluid management function from the cardiovascular system to the gastrointestinal system. By inhibiting NHE-mediated sodium and water absorption in the gut, fluid volume is reduced without affecting cardiac output or causing the systemic hemodynamic changes that lead to fatigue and dizziness.
Solution Approach 2:
The invention uses locally-acting non-absorbable compounds confined to the GI tract, creating a localized effect on fluid absorption without systemic circulation. This ensures fluid reduction occurs through GI mechanisms alone, avoiding the cardiovascular side effects (fatigue, dizziness) associated with systemic diuretic therapy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The indane derivatives effectively manage fluid and salt retention and gastrointestinal disorders with reduced risk of renal impairment and systemic complications, offering a broad spectrum of therapeutic benefits including pain reduction and improved treatment outcomes.
Implementation Method 1
inhibit NHE-mediated antiport of sodium ions and hydrogen ions
Data Source
Figure 1A~1D
Figure 2
AI summary
The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist- induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders.